Business

Novartis reportedly nears deal to buy cholesterol drugmaker Medicines Company for $7 billion

A logo sits on display on a building at the Novartis AG campus in Basel, Switzerland, on Wednesday, Jan. 16, 2019.

Stefan Wermuth | Bloomberg | Getty Images

Swiss pharmaceutical giant Novartis is close to a deal to purchase the cholesterol drugmaker Medicines Company for nearly $7 billion, according to The Wall Street Journal, which cited people familiar with the matter.

Novartis has agreed to pay $85 a share for Medicines Company in a deal that could be reached this weekend, according to The Journal.

The deal would strengthen the Swiss pharma giant’s position in the market for heart treatments, The Journal reported. Novartis, which has a market value of over $200 billion, is already targeting that market with drugs such as the heart-failure treatment Entresto. 

However, Entresto’s early sales have not met Wall Street’s expectations, according to The Journal, though prescriptions have picked up with sales jumping to $430 million in the third quarter. 

Medicines closed down nearly 2% Friday at 68.55 a share. The company, which has a market cap of about $5.4 billion, is up 258% year to date. 

Read the full story in The Wall Street Journal

Products You May Like

Articles You May Like

Mark Cuban still follows this advice his dad gave him at age 14: It helps me live ‘the way I wanted to’
This IRS issue is ‘the biggest, most consistent problem’ for taxpayers, expert says
Issues with new FAFSA may cause ‘shocking’ decline in the number of students getting college aid, expert says
Yum China CEO says consumers are growing more ‘rational’ as rising costs cut dining budgets
Zoom shares jump as quarterly results beat on top and bottom lines

Leave a Reply

Your email address will not be published. Required fields are marked *